Online Exclusive Article

Head's Up on the Treatment of Malignant Glioma Patients

Terri S. Armstrong

low-grade glioma
ONF 2009, 36(5), E232-E240. DOI: 10.1188/09.ONF.E232-E240

Jump to a section


    American Cancer Society. (2009). Cancer facts and figures, 2009. Atlanta, GA: Author.
    Armstrong, T.S., Cohen, M.Z., Weinberg, J., & Gilbert, M.R. (2004). Imaging techniques in neuro-oncology. Seminars in Oncology Nursing, 20(4), 231-239.
    Armstrong, T.S., Kanusky, J.T., & Gilbert, M.R. (2003). Seize the moment to learn about epilepsy in people with cancer. Clinical Journal of Oncology Nursing, 7(2), 163-169.
    Bohan, E., & Glass-Macenka, D. (2004). Surgical management of patients with primary brain tumors. Seminars in Oncology Nursing, 20(4), 240-252.
    Bondy, M.L., Scheurer, M.E., Malmer, B., Barnholtz-Sloan, J.S., Davis, F.G., Il'yasova, D., et al. (2008). Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium. Cancer, 113(7, Suppl.), 1953-1968.
    Brandes, A.A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., et al. (2008). MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Journal of Clinical Oncology, 26(13), 2192-2197.
    Brandes, A.A., Tosoni, A., Spagnolli, F., Frezza, G., Leonardi, M., Calbucci, F., et al. (2008). Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro-Oncology, 10(3), 361-367.
    Bromberg, J.E., & van den Bent, M.J. (2009). Oligodendrogliomas: Molecular biology and treatment. Oncologist, 14(2), 155-163.
    Cardis, E., Richardson, L., Deltour, I., Armstrong, B., Feychting, M., Johansen, C., et al. (2007). The INTERPHONE study: Design, epidemiological methods, and description of the study population. European Journal of Epidemiology, 22(9), 647-664.
    Catt, S., Chalmers, A., & Fallowfield, L. (2008). Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncology, 9(9), 884-891.
    Central Brain Tumor Registry of the United States. (2008). Statistical report: Primary brain tumors in the United States, 2000-2004. Hinsdale, IL: Author.
    Chamberlain, M.C. (2009). Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology, 72(8), 772-774.
    Chamberlain, M.C., Glantz, M.J., Chalmers, L., Van Horn, A., & Sloan, A.E. (2007). Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. Journal of Neuro-Oncology, 82(1), 81-83.
    Chang, J.E., Khuntia, D., Robins, H.I., & Mehta, M.P. (2007). Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clinical Advances in Hematology Oncology, 5(11), 894-902, 907-815.
    Chang, S.M., Kuhn, J.G., Robins, H.I., Schold, S.C., Jr., Spence, A.M., Berger, M.S., et al. (2001). A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: A North American Brain Tumor Consortium report. Cancer, 91(2), 417-422.
    Chang, S.M., Lamborn, K.R., Kuhn, J.G., Yung, W.K., Gilbert, M.R., Wen, P.Y., et al. (2008). Neuro-oncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium. Neuro-Oncology, 10(4), 631-642.
    Desjardins, A., Rich, J.N., Quinn, J.A., Vredenburgh, J., Gururangan, S., Sathornsumetee, S., et al. (2005). Chemotherapy and novel therapeutic approaches in malignant glioma. Frontiers in Bioscience, 10, 2645-2668.
    Drappatz, J., Schiff, D., Kesari, S., Norden, A.D., & Wen, P.Y. (2007). Medical management of brain tumor patients. Neurologic Clinics, 25(4), 1035-1071.
    Duran, I., & Raizer, J.J. (2007). Low-grade gliomas: Management issues. Expert Review of Anticancer Therapy, 7(12, Suppl.), S15-S21.
    Faithfull, S., Cook, K., & Lucas, C. (2005). Palliative care of patients with a primary malignant brain tumor: Case review of service use and support provided. Palliative Medicine, 19(7), 545-550.
    Fine, H.A., Dear, K.B., Loeffler, J.S., Black, P.M., & Canellos, G.P. (1993). Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer, 71(8), 2585-2597.
    Fisher, J.L., Schwartzbaum, J.A., Wrensch, M., & Wiemels, J.L. (2007). Epidemiology of brain tumors. Neurologic Clinics, 25(4), 867-890.
    Furnari, F.B., Fenton, T., Bachoo, R.M., Mukasa, A., Stommel, J.M., Stegh, A., et al. (2007). Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes and Development, 21(21), 2683-2710.
    Gerber, D.E., Grossman, S.A., & Streiff, M.B. (2006). Management of venous thromboembolism in patients with primary and metastatic brain tumors. Journal of Clinical Oncology, 24(8), 1310-1318.
    Gilbert, M.R., Supko, J.G., Batchelor, T., Lesser, G., Fisher, J.D., Piantadosi, S., et al. (2003). Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clinical Cancer Research, 9(8), 2940-2949.
    Gilbert, S.J., Singhrao, S.K., Khan, I.M., Gonzalez, L.G., Thomson, B.M., Burdon, D., et al. (2009). Enhanced tissue integration during cartilage repair in vitro can be achieved by inhibiting chondrocyte death at the wound edge. Tissue Engineering. Part A, 15(7), 1739-1749.
    Glantz, M.J., Cole, B.F., Forsyth, P.A., Recht, L.D., Wen, P.Y., Chamberlain, M.C., et al. (2000). Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 54(10), 1886-1893.
    Gonzalez, J., & Gilbert, M.R. (2005). Treatment of astrocytomas. Current Opinions in Neurology, 18(6), 632-638.
    Graham, C.A., & Cloughesy, T.F. (2004). Brain tumor treatment: Chemotherapy and other new developments. Seminars in Oncology Nursing, 20(4), 260-272.
    Hancock, C.M., & Burrow, M.A. (2004). The role of radiation therapy in the treatment of central nervous system tumors. Seminars in Oncology Nursing, 20(4), 253-259.
    Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352(10), 997-1003.
    Jackson, R.J., Fuller, G.N., Abi-Said, D., Lang, F.F., Gokaslan, Z.L., Shi, W.M., et al. (2001). Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-Oncology, 3(3), 193-200.
    Kan, P., Simonsen, S.E., Lyon, J.L., & Kestle, J.R. (2008). Cellular phone use and brain tumor: A meta-analysis. Journal of Neuro-Oncology, 86(1), 71-78.
    Lacroix, M., Abi-Said, D., Fourney, D.R., Gokaslan, Z.L., Shi, W., DeMonte, F., et al. (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. Journal of Neurosurgery, 95(2), 190-198.
    Lahkola, A., Auvinen, A., Raitanen, J., Schoemaker, M.J., Christensen, H.C., Feychting, M., et al. (2007). Mobile phone use and risk of glioma in five North European countries. International Journal of Cancer, 120(8), 1769-1775.
    Lee, E.L., & Armstrong, T.S. (2008). Increased intracranial pressure. Clinical Journal of Oncology Nursing, 12(1), 37-41.
    Litofsky, N.S., & Resnick, A.G. (2009). The relationships between depression and brain tumors. Journal of Neuro-Oncology. [Epub ahead of print].
    Loghin, M.E., Prados, M.D., Wen, P., Junck, L., Lieberman, F., Fine, H., et al. (2007). Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study. Clinical Cancer Research, 13(23), 7133-7138.
    Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., et al. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica, 114(2), 97-109.
    Lovely, M.P. (1998). Quality of life of brain tumor patients. Seminars in Oncology Nursing, 14(1), 73-80.
    Lovely, M.P. (2004). Symptom management of brain tumor patients. Seminars in Oncology Nursing, 20(4), 273-283.
    Marras, L.C., Geerts, W.H., & Perry, J.R. (2000). The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review. Cancer, 89(3), 640-646.
    Mason, W.P., & Cairncross, J.G. (2008). Invited article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas. Neurology, 71(5), 365-373.
    Meyers, C.A., Weitzner, M.A., Valentine, A.D., & Levin, V.A. (1998). Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. Journal of Clinical Oncology, 16(7), 2522-2527.
    Ohgaki, H., & Kleihues, P. (2007). Genetic pathways to primary and secondary glioblastoma. American Journal of Pathology, 170(5), 1445-1453.
    Ron, E., Modan, B., Boice, J.D., Jr., Alfandary, E., Stovall, M., Chetrit, A., et al. (1988). Tumors of the brain and nervous system after radiotherapy in childhood. New England Journal of Medicine, 319(16), 1033-1039.
    Ryken, T.C., Frankel, B., Julien, T., & Olson, J.J. (2008). Surgical management of newly diagnosed glioblastoma in adults: Role of cytoreductive surgery. Journal of Neuro-Oncology, 89(3), 271-286.
    Sadetzki, S., Modan, B., Chetrit, A., & Freedman, L. (2000). An iatrogenic epidemic of benign meningioma. American Journal of Epidemiology, 151(3), 266-272.
    Sathornsumetee, S., Cao, Y., Marcello, J.E., Herndon, J.E., 2nd, McLendon, R.E., Desjardins, A., et al. (2008). Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. Journal of Clinical Oncology, 26(2), 271-278.
    Sathornsumetee, S., & Rich, J.N. (2008). Designer therapies for glioblastoma multiforme. Annals of the New York Academy of Science, 1142, 108-132.
    Schabet, M. (1999). Epidemiology of primary CNS lymphoma. Journal of Neuro-Oncology, 43(3), 199-201.
    Scheurer, M.E., El-Zein, R., Thompson, P.A., Aldape, K.D., Levin, V.A., Gilbert, M.R., et al. (2008). Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiology, Biomarkers, and Prevention, 17(5), 1277-1281.
    Schiff, D., Suman, V.J., Yang, P., Rocca, W.A., & O'Neill, B.P. (1998). Risk factors for primary central nervous system lymphoma: A casecontrol study. Cancer, 82(5), 975-982.
    Schoemaker, M.J., Swerdlow, A.J., Ahlbom, A., Auvinen, A., Blaasaas, K.G., Cardis, E., et al. (2005). Mobile phone use and risk of acoustic neuroma: Results of the Interphone Case-Control Study in five North European countries. British Journal of Cancer, 93(7), 842-848.
    Sciacca, F.L., Ciusani, E., Silvani, A., Corsini, E., Frigerio, S., Pogliani, S., et al. (2004). Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clinical Cancer Research, 10(4), 1312-1317.
    Simon, M., & Schramm, J. (2009). Surgical management of intracranial gliomas. Recent Results in Cancer Research, 171, 105-124.
    Souhami, L., Seiferheld, W., Brachman, D., Podgorsak, E.B., Werner-Wasik, M., Lustig, R., et al. (2004). Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. International Journal of Radiation Oncology, Biology, and Physics, 60(3), 853-860.
    Stevens, G.H. (2006). Antiepileptic therapy in patients with central nervous system malignancies. Current Neurology and Neuroscience Reports, 6(4), 311-318.
    Stupp, R., Hegi, M.E., Mason, W.P., van den Bent, M.J., Taphoorn, M.J., Janzer, R.C., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: Five-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10(5), 459-466.
    Stupp, R., Hegi, M.E., van den Bent, M.J., Mason, W.P., Weller, M., Mirimanoff, R.O., et al. (2006). Changing paradigms—An update on the multidisciplinary management of malignant glioma. Oncologist, 11(2), 165-180.
    Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987-996.
    Ueki, K., Nishikawa, R., Nakazato, Y., Hirose, T., Hirato, J., Funada, N., et al. (2002). Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clinical Cancer Research, 8(1), 196-201.
    U.S. Food and Drug Administration. (2009). FDA approves drug for treatment of aggressive brain cancer. Retrieved August 12, 2009, from
    Van den Bent, M.J., Reni, M., Gatta, G., & Vecht, C. (2008). Oligodendroglioma. Critical Reviews in Oncology/Hematology, 66(3), 262-272.
    Vredenburgh, J.J., Desjardins, A., Herndon, J.E., 2nd, Dowell, J.M., Reardon, D.A., Quinn, J.A., et al. (2007). Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Research, 13(4), 1253-1259.
    Wagman, L.D., Baird, M.F., Bennett, C.L., Bockenstedt, P.L., Cataland, S.R., Fanikos, J., et al. (2008). Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 6(8), 716-753.
    Walker, M.D., Alexander, E., Jr., Hunt, W.E., MacCarty, C.S., Mahaley, M.S., Jr., Mealey, J., Jr., et al. (1978). Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. Journal of Neurosurgery, 49(3), 333-343.
    Wen, P.Y., & Kesari, S. (2008). Malignant gliomas in adults. New England Journal of Medicine, 359(5), 492-507.
    Westcarth, L., & Armstrong, T. (2007). Seizures in people with cancer. Clinical Journal of Oncology Nursing, 11(1), 33-37.
    Westphal, M., Hilt, D.C., Bortey, E., Delavault, P., Olivares, R., Warnke, P.C., et al. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology, 5(2), 79-88.
    Zuniga, R.M., Torcuator, R., Jain, R., Anderson, J., Doyle, T., Ellika, S., et al. (2009). Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. Journal of Neuro-Oncology, 91(3), 329-336.